Citations 2
Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology
Advani, Ranjana H., Kelsey, C., Armand, Philippe, Bello, Celeste, Benitez, Cecil M. , Chen, Weina , Cherian, Sheen , Czader, Magdalena , Dabaja, Bouthaina, Daly, Megan E., Gordon, L. I., Hansen, Neil, Herrera, Alex F. , Hochberg, Ephraim P. , Hoppe, Richard T., Isufi, Iris, Johnston, Patrick B., Kelly, Kara M, Kenkre, Vaishalee P. , Lynch, R., Morgan, David, Rabinovitch, R., Salavati, Ali, Sano, Dahlia , Svoboda, J., Yahalom, Joachim, Yang, Joanna C. , Stehman, Katie, Advani, Ranjana H. , Hoppe, Richard T. , Advani, Ranjana H , Hoppe, Richard T , Kelsey, Chris R. , Armand, Philippe , Bond, David A. , Dabaja, Bouthaina, Daly, Megan, Frosch, Zachary AK , Hansen, Neil, Johnston, Patrick B, Kelly, Kara M , Kline, Justin Paul , McConathy, Jonathan , Niu, Alex , Paul, Suman , Rabinovitch, Rachel , Salavati, Ali , Shah, Harsh , Spinner, Michael A. , Svoboda, Jakub , Winter, Jane N. , Yahalom, Joachim , Montgomery, Sarah E.
Journal of the National Comprehensive Cancer Network | February 9, 2026 | Volume: 24 | Issue: 2 | Pages: 41-60
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hodgkin lymphoma provide expert, multidisciplinary recommendations for the diagnosis and treatment of Hodgkin lymphoma. The panel convenes annually to update recommendations based on a review of recently published clinical trials. This selection from the NCCN Guidelines for Hodgkin Lymphoma focuses on the management of newly diagnosed and relapsed/refractory classic Hodgkin lymphoma in adults aged 18 to 60 years.
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022
Hoppe, Richard T. , Advani, Ranjana H. , Ambinder, Richard F. , Armand, Philippe , Bello, Celeste, Benitez, Cecil M. , Chen, Weina , Dabaja, Bouthaina S. , Daly, Megan E. , Hansen, Neil, Herrera, Alex F. , Hochberg, Ephraim P. , Johnston, Patrick B. , Kaminski, Mark , Kenkre, Vaishalee P. , Lynch, Ryan C. , Maddocks, Kami J. , Metzger, Monika L. , Morgan, David , Mulroney, Carolyn , Pullarkat, Sheeja T. , Rabinovitch, Rachel , Rosenspire, Karen C., Seropian, Stuart , Tao, Randa , Torka, Pallawi , Yang, Joanna C. , Burns, Jennifer L. , Campbell, Mallory, Sundar, Hema, Advani, Ranjana H , Hoppe, Richard T , Ambinder, Richard F , Tao, Randa , Ai, Weiyun Z. , Gordon, Leo I. , Kelsey, Chris R. , Khan, Nadia , McConathy, Jonathan , Winter, Jane N. , Yahalom, Joachim
Journal of the National Comprehensive Cancer Network | April 7, 2022 | Volume: 20 | Issue: 4 | Pages: 322-334
Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL) and nodular lymphocyte–predominant HL are the 2 main types of HL. The cure rates for HL have increased so markedly with the advent of modern treatment options that overriding treatment considerations often relate to long-term toxicity. These NCCN Guidelines Insights discuss the recent updates to the NCCN Guidelines for HL focusing on (1) radiation therapy dose constraints in the management of patients with HL, and (2) the management of advanced-stage and relapsed or refractory cHL.